Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Samsung Pharmaceutical Co., Ltd. (001360:KRX), powered by AI.
Samsung Pharmaceutical Co., Ltd. is currently trading at ₩2,090. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Samsung Pharmaceutical Co., Ltd. on Alpha Lenz.
Samsung Pharmaceutical Co., Ltd.'s P/E ratio is -13.4.
“Samsung Pharmaceutical Co., Ltd. trades at a P/E of -13.4 (undervalued) with modest ROE of -15.4%.”
Ask for details →Samsung Pharmaceutical Co., Ltd. is a prominent entity in the pharmaceutical industry, primarily engaged in the research, development, and manufacturing of pharmaceutical and healthcare products. This company plays a key role in addressing diverse healthcare needs by producing a variety of drugs and medical solutions, which include over-the-counter medications, prescription drugs, and other specialized therapeutic products. Samsung Pharmaceutical operates at the intersection of science and healthcare, striving to enhance patient outcomes and overall public health. The company is recognized for its commitment to innovation and quality, leveraging advanced technology and rigorous scientific research to develop effective medical treatments. Operating within highly regulated markets, the company ensures compliance with stringent pharmaceutical standards and regulations, thus maintaining credibility and trust among healthcare professionals and consumers alike. As part of its broader impact, Samsung Pharmaceutical contributes to the healthcare sector by addressing unmet medical needs and supporting the advancement of medical science. It is a significant player in the pharmaceutical market, influencing drug pricing, healthcare access, and fostering pharmaceutical advancements across various regions.
“Samsung Pharmaceutical Co., Ltd. trades at a P/E of -13.4 (undervalued) with modest ROE of -15.4%.”
Ask for details →Samsung Pharmaceutical Co., Ltd. (ticker: 001360) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). Market cap is $196.8B.
The current price is ₩2,090 with a P/E ratio of -13.38x and P/B of 1.78x.
ROE is -15.36% and operating margin is -33.48%. Annual revenue is $44.3B.